Créée en 2005, l’Unité U932 INSERM est composée de 10 équipes, réparties sur deux bâtiments (Hôpital Curie et Bâtiment Constant-Burg, rue Lhomond), regroupant environ 160 personnes.

Les équipes de l’Unité tentent de mieux comprendre les réponses immunitaires, et d’apprendre au système immunitaire à mieux lutter contre les agents pathogènes et/ou les tumeurs. Les projets de recherche vont de l’immunologie fondamentale à l’immunothérapie translationnelle et à l’immunothérapie clinique chez des patients atteints de cancer.

 

Chiffres-clés
334
Publications depuis 2017
11
ERC depuis 2008
3
start-ups
Publications clés
Toutes les publications
Actualités
Toutes les actualités
Événements scientifiques
10 juin
2024
Séminaire
11h-23h
Centre de recherche - Paris - Amphithéâtre Constant-Burg - 12 rue Lhomond, Paris 5e
Functional and molecular characterization of cancer-derived extracellular vesicles
Cancer-derived extracellular vesicles have been demonstrated to play a crucial role in cancer biology. Our team is particularly interested in cancer EV heterogeneity and we have been studying a particular population of extracellular vesicles, known as large oncosomes. These EVs are released by aggressive cancer cells that exhibit cell plasticity and have acquired metastatic abilities.  I will
21 mai
2024
Séminaire
11h-23h
Centre de recherche - Paris - Amphithéâtre Constant-Burg - 12 rue Lhomond, Paris 5e
Nucleosomes and DNA methylation – implications for immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome and cancers
DNA methylation is a broadly observed epigenetic modification. As genomic DNA methylation profiles dynamically change during development and aging, alterations in DNA methylation patterns are linked to diseases such as cancers and immunodeficiency. ICF syndrome is characterized by hypomethylation at heterochromatin. Of four proteins whose mutation cause ICF syndromes (DNMT3B, ZBTB24, CDCA7 and HEL
13 mai
2024
Séminaire
11h-23h
Hôpital site de Paris - Amphithéâtre Hélène Martel-Massignac (BDD)
“Deconstruct-Reconstruct” – Decode cancer-immune crosstalk & probe with organoids.
The Roose team at UCSF studies mechanisms of cell-cell interactions in immunology and cancer1-7, with emphasis on personalized medicine4,8 and single cell approaches9-11. Over the past 7 years, we shifted a large portion of our research efforts to understanding human biology and disease. We are deeply interested in the cellular networks that underpin autoimmune diseases and cancer, which I will ta
3 mai
2024
Séminaire
11h-23h
Centre de recherche - Paris - Amphithéâtre Constant-Burg - 12 rue Lhomond, Paris 5e
Understanding and modeling aging
Aging is associated with a decline in tissue function and the onset of a constellation of diseases. We are interested in understanding aging, with a particular focus on brain aging. Because aging is complex, we use organisms with diverse lifespans – the worm C. elegans, the African killifish, the mouse, and cells from mice and humans. We are interested in identifying epigenetic and metabolic
27 Mar
2024
Séminaire
15h-23h
Centre de recherche - Paris - Amphithéâtre Constant-Burg - 12 rue Lhomond, Paris 5e
Regulation and immunotherapy responses of NK cells (and T cells) against tumors
Most immunotherapy efforts aim to mobilize CD8+ T cells against cancer cells. Many tumors lack many neoantigens, and others are selected for partial or complete loss of MHC I, even before immunotherapy intervention.  Checkpoint immunotherapy further exacerbates this problem as it preferentially amplifies CD8 cytotoxic effector cell activity, which targets MHC I presented tumor epitopes, impos
Tous les événements scientifiques
Offres d'emploi
Aucune offre d'emploi disponible.
Toutes les offres